Sanofi has signed a licence agreement to develop Principia Biopharma’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246), which is currently in clinical development.

Principia’s experimental oral treatment shows promise in multiple sclerosis (MS) and potentially other central nervous system (CNS) diseases.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

PRN2246 will access the brain and spinal cord by crossing the blood-brain barrier and impact immune cell and brain cell signalling.

Sanofi MS / Neuroscience Therapeutic Research Area global head Rita Balice-Gordon said: “Our agreement with Principia is an example of Sanofi’s strategic commitment to build our drug discovery and development pipeline in MS and neurological diseases.

“Complementing our own internal R&D expertise and external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases.”

“Complementing our own internal R&D expertise and external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases.”

Under the agreement, Principia will grant an exclusive, worldwide licence to Sanofi for the development and commercialisation of PRN2246.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will receive a $40m upfront payment, $765m future milestone payments and royalties on product sales, from Sanofi.

Principia Biopharma CEO Martin Babler said: “The agreement allows Principia to maximise the BTK opportunity in neurology with a strong partner for PRN2246 while focusing internal resources on our lead BTK inhibitor in another therapeutic area.

“PRN2246 is a blood-brain barrier crossing, highly potent BTK inhibitor, that we believe is especially well suited for the treatment of MS and other neurological disorders.”

The transaction is subject to customary regulatory approvals and is expected to close in the fourth quarter of this year.